Table 1.
Univariable and multivariable analyses of PFS in patients with nonsquamous NSCLC or squamous NSCLC.
| Nonsquamous NSCLC | ICI treatment (n = 349) | Chemotherapy (n = 224) | Interaction effect (n = 573) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | ||||||
| HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
| Age (≥65 vs. <65) | 1.06 (0.81–1.39) | 0.659 | 0.94 (0.72–1.24) | 0.680 | 1.00 (0.82–1.21) | 0.970 | ||||||
| Sex (male vs. female) | 0.81 (0.64–1.02) | 0.069 | 0.79 (0.58–1.08) | 0.144 | 1.02 (0.78–1.35) | 0.872 | 0.88 (0.74–1.05) | 0.169 | ||||
| Race (white vs. nonwhite) | 0.81 (0.62–1.04) | 0.099 | 1.02 (0.75–1.39) | 0.900 | 0.99 (0.74–1.33) | 0.954 | 0.88 (0.72–1.06) | 0.184 | ||||
| Smoking (smoker vs. non-smoker) | 0.72 (0.55–0.95) | 0.022 | 0.80 (0.55–1.16) | 0.245 | 1.00 (0.71–1.42) | 0.984 | 0.80 (0.64–0.99) | 0.040 | 0.83 (0.65–1.06) | 0.142 | ||
| ECOG (≥1 vs. 0) | 1.21 (0.94–1.56) | 0.145 | 1.40 (1.05–1.86) | 0.021 | 1.35 (1.01–1.80) | 0.040 | 1.26 (1.04–1.53) | 0.016 | 1.49 (1.21–1.84) | <0.001 | ||
| Metastatic sites (≥3 vs. <3) | 1.51 (1.16–1.97) | 0.002 | 1.61 (1.19–2.17) | 0.002 | 1.55 (1.15–2.08) | 0.004 | 1.40 (1.04–1.89) | 0.027 | 1.49 (1.23–1.81) | <0.001 | 1.49 (1.21–1.84) | <0.001 |
| Treatment lines (≥3 vs. 2 vs. 1) | 1.25 (1.06–1.47) | 0.007 | 0.73 (0.53–1.00) | 0.048 | 0.72 (0.53–0.98) | 0.036 | 0.72 (0.53–0.98) | 0.037 | 1.15 (1.01–1.32) | 0.035 | 0.70 (0.56–0.87) | 0.001 |
| PD-L1 (positive vs. negative) | 0.73 (0.58–0.92) | 0.007 | 0.82 (0.61–1.09) | 0.173 | 0.93 (0.71–1.23) | 0.624 | 0.94 (0.71–1.24) | 0.660 | 0.79 (0.67–0.95) | 0.010 | 0.89 (0.73–1.08) | 0.240 |
| TMB ( ≥ median vs. <median) | 0.79 (0.63–1.00) | 0.046 | 1.56 (1.14–2.13) | 0.005 | 1.74 (1.32–2.31) | <0.001 | 1.59 (1.17–2.17) | 0.003 | 1.00 (0.84-1.19) | 0.977 | 1.57 (1.25-1.96) | <0.001 |
| Inter-score (≤cut-off vs. >cut-off) | 0.45 (0.33–0.61) | <0.001 | 0.45 (0.30–0.67) | <0.001 | 1.42 (1.02–1.98) | 0.039 | 1.16 (0.80–1.68) | 0.425 | 1.35 (0.97–1.88) | 0.077 | 1.13 (0.80–1.59) | 0.494 |
| Therapy (ICI vs. chemotherapy) | 1.08 (0.89–1.32) | 0.440 | 1.17 (0.94–1.46) | 0.158 | ||||||||
| Interaction: inter-score*therapy | 0.31 (0.20–0.49) | <0.001 | 0.38 (0.23–0.61) | <0.001 | ||||||||
| Squamous NSCLC | ICI treatment (n = 135) | Chemotherapy (n = 91) | Interaction effect (n = 226) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | ||||||
| HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
| Age (≥65 vs. <65) | 0.88 (0.57–1.36) | 0.570 | 1.63 (1.05–2.53) | 0.028 | 1.56 (1.00–2.42) | 0.049 | 1.12 (0.83–1.51) | 0.455 | ||||
| Sex (male vs. female) | 0.79 (0.46–1.36) | 0.398 | 1.40 (0.84–2.32) | 0.195 | 1.03 (0.72–1.49) | 0.861 | ||||||
| Race (white vs. nonwhite) | 1.00 (0.67–1.50) | 0.981 | 1.32 (0.79–2.21) | 0.283 | 1.16 (0.85–1.57) | 0.349 | ||||||
| Smoking (smoker vs. non-smoker) | 0.91 (0.44–1.89) | 0.805 | 0.66 (0.16-2.73) | 0.568 | 0.96 (0.51-1.83) | 0.908 | ||||||
| ECOG (≥1 vs. 0) | 1.40 (0.87–2.26) | 0.166 | 1.26 (0.78–2.02) | 0.344 | 1.28 (0.92–1.79) | 0.145 | ||||||
| Metastatic sites (≥3 vs. <3) | 1.30 (0.88–1.93) | 0.193 | 0.75 (0.48–1.15) | 0.185 | 1.11 (0.83–1.48) | 0.484 | ||||||
| Treatment lines (≥3 vs. 2 vs. 1) | 1.41 (1.06–1.87) | 0.019 | 1.53 (1.16–2.03) | 0.003 | 0.88 (0.46-1.67) | 0.697 | 1.35 (1.06–1.72) | 0.016 | 1.40 (1.09–1.78) | 0.007 | ||
| PD-L1 (positive vs. negative) | 0.99 (0.67–1.45) | 0.954 | 1.11 (0.75–1.64) | 0.599 | 1.27 (0.82–1.95) | 0.280 | 1.17 (0.76–1.80) | 0.483 | 1.04 (0.79–1.38) | 0.775 | 1.15 (0.87–1.54) | 0.328 |
| TMB ( ≥ median vs. <median) | 0.83 (0.57–1.21) | 0.340 | 0.69 (0.47–1.01) | 0.054 | 1.58 (1.02–2.44) | 0.040 | 1.52 (0.98–2.36) | 0.064 | 1.00 (0.76–1.32) | 1.000 | 0.97 (0.73–1.29) | 0.815 |
| Inter-score (≤cut-off vs. >cut-off) | 0.43 (0.29–0.64) | <0.001 | 0.37 (0.24–0.56) | <0.001 | 1.12 (0.71–1.78) | 0.616 | 1.14 (0.72–1.81) | 0.565 | 1.08 (0.69–1.70) | 0.741 | 1.07 (0.68-1.68) | 0.779 |
| Therapy (ICI vs. chemotherapy) | 1.03 (0.73–1.46) | 0.850 | 1.09 (0.77–1.56) | 0.619 | ||||||||
| Interaction: inter-score*therapy | 0.37 (0.20–0.69) | 0.001 | 0.35 (0.19–0.65) | <0.001 | ||||||||
CI confidence interval, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, PD-L1 programmed death-ligand 1, TMB tumor mutational burden.